Going back and forth is par for the course. The complexity that a simple change would have on a trial that is designed to meet two major market regulators can't be easy. One would hope or even demand that the back and forth communication are on going and changes are continuous so we can avoid poor trial design and potential missed endpoints (enter Charmaine's extensive trial experience). ANP have won the timing lottery on this aspect. Totally agree that trials aren't set loose without proof of funding to trial completion. That's why I believe that the approximate funding amount and the funding sources are a forgone conclusion and something that concerns me the least. I think they are rejecting way more offers than they are considering and this means they have total strategic choice in navigating their financial future. But as far as chronology goes, I don't think we will see the company talking about capital raising prior to PDCO feedback. Hope that explains it clearer.
ANP Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)